GreatPoint Energy Tops List of Biggest Massachusetts VC Deals of 2007
Good old 2007. Whether just starting out or going public, it was a fine year for many Massachusetts technology firms. In fact, as we reported last week, a bevy of four-quarter Boston area initial public offerings helped make last year the best IPO year for venture-backed companies since 2004. Today, we’re presenting the numbers on the biggest Bay State venture deals of 2007.
Not surprisingly, cost-heavy energy and biotech firms dominated the list. In fact, a pair of energy companies, GreatPoint Energy ($100 million) and A123 Systems ($70 million), claimed the first two slots, with another duo a bit farther down. Biopharmaceutical firms snared another four of the spots, leaving just a pair of IT firms in the top 10—one of which (Brightcove) is an Internet-based content distribution company, and the other (DarwinSuzsoft) is an outsourcing firm.
Here’s the list, with the lead investors behind them, as provided by Dow Jones VentureSource. All except Syndax Pharmaceuticals, which closed its first round of financing, were later stage deals.
Massachusetts’ Top 10 Venture Deals of 2007
GreatPoint Energy (Cambridge) — $100 million
Lead investor: Dow Chemical
A123Systems (Watertown) — $70 million
Lead investor: GE Capital Commercial Finance
Targanta Therapeutics (Cambridge) — $70 million
Lead investors: OrbiMed Advisors, Radius Ventures, Skyline Ventures.
Brightcove (Cambridge) — $59.5 million
Lead investors: AllianceBernstein, Maverick Capital
Aveo Pharmacecuticals* (Cambridge) — $53 million
Lead investors not identified.** New investors this round included: Biogen Idec, Bessemer Venture Partners, Merlin BioMed Group, Mitsubishi UFJ Financial Group, Schering-Plough Corporation, Vatera Holdings)
Microbia (Cambridge) — $50 million
Lead investor:** Ridgeback Capital
DarwinSuzsoft* (Wakefield) — $48 million
Lead investor: Francisco Partners
Konarka Technologies (Lowell) — $45 million
Lead investor: Good Energies
Boston-Power (Westborough) — $45 million
Lead investor: Oak Investment Partners
Syndax Pharmaceuticals (Waltham) — $40 million
Lead investor: Domain Associates
* company name not divulged by Dow Jones, but we were able to piece it together
** Investors not identified by Dow Jones, but…